EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological Immunomodulation via Collagen–Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study

Hugo Mendieta-Zerón iD, Esteban Cruz-Arenas iD, Salvador Díaz-Meza, Alejandro Cabrera-Wrooman, Edna Ayerim Mandujano-Tinoco, Rosa M Salgado, Hugo Tovar iD, Daniel Muñiz-García iD, Laura Julieta Orozco-Castañeda iD, Sonia Hernández-Enríquez, Miriam Deyanira Rodríguez-Piña, Ana Sarahí Mulia-Soto und 3 weitere

Advances in Respiratory Medicine · 2025

DOI: 10.3390/arm93040024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Respiratory Medicine, 2025. Verfasst von Hugo Mendieta-Zerón und 14 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca 50000, State of Mexico, Mexico. Hauptthemen laut MEDLINE: Pyridones, COVID-19 Drug Treatment, Collagen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic target of COVID-19 is focused on controlling inflammation and preventing fibrosis. Collagen–polyvinylpyrrolidone (collagen-PVP) and pirfenidone both have the ability to control the cytokine storm observed in rheumatic and fibrotic disorders. In this work, our aim was to understand the benefits of treatment with each of these drugs in patients with severe COVID-19. In total, 36 patients were treated with dexamethasone and enoxaparin, but 26 were allocated collagen-PVP or pirfenidone (n = 15 and 11, respectively); the clinical and metabolic effects were compared among them. Since pirfenidone works via transcriptional mechanisms, we performed a human genome microarray assay using RNA isolated from fibroblast and monocyte cultures treated with the biodrug, with the aim of hypothesising a possible mechanism of action for collagen-PVP. Our results showed that hospital stay duration, quick COVID-19 severity index (qCSI), and admission to the intensive care unit were statistically significantly lower (p < 0.02) in patients treated with collagen-PVP or pirfenidone when compared with the control group, and that only collagen-PVP normalised serum glucose at discharge. Ingenuity Pathway Analysis showed that the cell cycle, inflammation, and cell surface–extracellular matrix interactions could be regulated with collagen-PVP via the downmodulation of proinflammatory cytokines, while Th2 anti-inflammatory response signalling could be upregulated. Furthermore, the downregulation of some of the genes involved in nitric oxide production showed a possible control for JAK in the IFN-γ pathway, allowing for the possibility of controlling inflammation through the JAK/STAT pathway, as has been observed for pirfenidone and other immunomodulators, such as ruxolitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesCOVID-19 Drug TreatmentCollagenHumansPilot ProjectsMaleFemaleMiddle AgedCOVID-19Signal TransductionJanus KinasesSTAT Transcription FactorsAgedSARS-CoV-2Anti-Inflammatory Agents, Non-Steroidal

Stichwörter der Autor:innen

SARS-CoV-2collagen–polyvinylpyrrolidoneinflammationpirfenidone

Substanzen

PyridonespirfenidoneJanus KinasesCollagenSTAT Transcription FactorsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca 50000, State of Mexico, Mexico.
  • Hospital Materno-Perinatal 'Mónica Pretelini Sáenz', Toluca 50140, State of Mexico, Mexico.
  • Epidemiological Vigilance Unit, Instituto Nacional de Rehabilitación 'Luis Guillermo Ibarra Ibarra', Mexico City 14389, Mexico.
  • Hospital General 'Dr. Nicolás San Juan', Toluca 50010, State of Mexico, Mexico.
  • Laboratory of Connective Tissue, Centro Nacional de Investigación y Atención de Quemados, Instituto Nacional de Rehabilitación 'Luis Guillermo Ibarra Ibarra', Mexico City 14389, Mexico.
  • Computational Genomics Division, National Institute of Genomic Medicine, Mexico City 14610, Mexico.

ORCID-Profile: Hugo Mendieta-Zerón, Esteban Cruz-Arenas, Hugo Tovar, Daniel Muñiz-García, Laura Julieta Orozco-Castañeda, Edgar Krötzsch

Zitieren

APA

Mendieta-Zerón, H., Cruz-Arenas, E., Díaz-Meza, S., Cabrera-Wrooman, A., Mandujano-Tinoco, E. A., Salgado, R. M., Tovar, H., Muñiz-García, D., Orozco-Castañeda, L. J., Hernández-Enríquez, S., Rodríguez-Piña, M. D., Mulia-Soto, A. S., Meneses-Calderón, J., Mondragón-Terán, P., & Krötzsch, E. (2025). Pharmacological Immunomodulation via Collagen–Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study. Advances in Respiratory Medicine. https://doi.org/10.3390/arm93040024

Vancouver

Mendieta-Zerón H, Cruz-Arenas E, Díaz-Meza S, Cabrera-Wrooman A, Mandujano-Tinoco EA, Salgado RM, et al. Pharmacological Immunomodulation via Collagen–Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study. Advances in Respiratory Medicine. 2025. doi:10.3390/arm93040024

BibTeX
@article{MendietaZern2025,
  author = {Mendieta-Zerón, Hugo and Cruz-Arenas, Esteban and Díaz-Meza, Salvador and Cabrera-Wrooman, Alejandro and Mandujano-Tinoco, Edna Ayerim and Salgado, Rosa M and Tovar, Hugo and Muñiz-García, Daniel and Orozco-Castañeda, Laura Julieta and Hernández-Enríquez, Sonia and Rodríguez-Piña, Miriam Deyanira and Mulia-Soto, Ana Sarahí and Meneses-Calderón, José and Mondragón-Terán, Paul and Krötzsch, Edgar},
  title = {Pharmacological Immunomodulation via Collagen–Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study},
  journal = {Advances in Respiratory Medicine},
  year = {2025},
  doi = {10.3390/arm93040024}
}
Kostenlos starten →